Search research articles
Contact Us
Filters
Showing results (1-10 of 24) with videos related to
Page
of 3
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 13, 2018
Targeting cell cycle dependencies represent a novel therapeutic approach for selected sarcoma subgroups
J Adam, S Postel-Vinay
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 8, 2018
Phase I-II trial designs: how early should efficacy guide the dose recommendation process?
X Paoletti, S Postel-Vinay
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 2, 2014
Phase I trials in oncology: a new era has started
S Postel-Vinay, J-C Soria
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 10, 2016
Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape
K A Olaussen, S Postel-Vinay
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 30, 2013
Tumour markers fluctuations in patients with medullary thyroid carcinoma receiving long-term RET inhibitor therapy: ordinary lapping or alarming waves foreshadowing disease progression?
S Postel-Vinay, M Schlumberger, J-C Soria
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 21, 2017
Targeting chromatin defects in selected solid tumors based on oncogene addiction, synthetic lethality and epigenetic antagonism
D Morel, G Almouzni, J-C Soria, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 13, 2018
Epigenetic modifiers as new immunomodulatory therapies in solid tumours
S Aspeslagh, D Morel, J-C Soria, et al.
Bulletin Du Cancer
|
January 12, 2011
[Dose finding methods for targeted agents: new perspectives]
X Paoletti, S Postel-Vinay, V Servois, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 19, 2015
Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies
S Postel-Vinay, S Aspeslagh, E Lanoy, et al.
British Journal of Cancer
|
April 30, 2009
Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?
S Postel-Vinay, H-T Arkenau, D Olmos, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 24) with videos related to
Sort By:
Page
of 3
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 13, 2018
Targeting cell cycle dependencies represent a novel therapeutic approach for selected sarcoma subgroups
J Adam, S Postel-Vinay
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 8, 2018
Phase I-II trial designs: how early should efficacy guide the dose recommendation process?
X Paoletti, S Postel-Vinay
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 2, 2014
Phase I trials in oncology: a new era has started
S Postel-Vinay, J-C Soria
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 10, 2016
Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape
K A Olaussen, S Postel-Vinay
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 30, 2013
Tumour markers fluctuations in patients with medullary thyroid carcinoma receiving long-term RET inhibitor therapy: ordinary lapping or alarming waves foreshadowing disease progression?
S Postel-Vinay, M Schlumberger, J-C Soria
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 21, 2017
Targeting chromatin defects in selected solid tumors based on oncogene addiction, synthetic lethality and epigenetic antagonism
D Morel, G Almouzni, J-C Soria, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 13, 2018
Epigenetic modifiers as new immunomodulatory therapies in solid tumours
S Aspeslagh, D Morel, J-C Soria, et al.
Bulletin Du Cancer
|
January 12, 2011
[Dose finding methods for targeted agents: new perspectives]
X Paoletti, S Postel-Vinay, V Servois, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 19, 2015
Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies
S Postel-Vinay, S Aspeslagh, E Lanoy, et al.
British Journal of Cancer
|
April 30, 2009
Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?
S Postel-Vinay, H-T Arkenau, D Olmos, et al.
Page
of 3